A drug from Amgen could give patients with an aggressive form of lung cancer significantly more time to live when added to an immunotherapy from AstraZeneca.

Log in or sign up to comment.

No comments yet.

← Back to stories

Create FREE account

or login to continue

Signup with GoogleSignup with GitHubSignup with BlueskySignup with Blacksky
Sign up with email

Already have an account? Log in